Investment
Features
FeesSafety
Academy
More
Pluang+

Digi Power X insiders buy shares, signaling confidence in company prospects.

Market News
24 Aug 2026
Proactive Investors
View Source
Bullish
pluang ai news

Digi Power X Inc insiders, including President Amar Alec and CEO Michel Amar, purchased shares in recent open-market transactions. Alec bought 10,000 shares at an average price of $3.86, while Amar acquired 20,000 shares at $3.60 each. These purchases increase their ownership stakes and suggest management's confidence in the company's future. Digi Power X operates AI infrastructure with power assets and data centers in Alabama, New York, and North Carolina.

More News (DGX)

Quest Diagnostics CEO to discuss company strategy and market trends at Baird Healthcare Conference Sept 15

Quest Diagnostics CEO to discuss company strategy and market trends at Baird Healthcare Conference Sept 15

Quest Diagnostics announced that CEO Jim Davis will present the company's strategy, performance, and insights on market trends at the Baird 2026 Global Healthcare Conference in New York on September 15, 2026. The session will include a fireside chat ...

Market News
Neutral
2 days ago
Humanity Biological Age test now available in the U.S. via Quest's platform for $29 add-on.

Humanity Biological Age test now available in the U.S. via Quest's platform for $29 add-on.

Humanity Health Inc. and Quest Diagnostics have launched the Humanity Biological Age test in the U.S. through Quest's consumer platform questhealth.com. For $29, individuals can add this test to select health profiles without extra blood draws, recei...

Market News
Bullish
2 days ago
Quest Diagnostics CFO to discuss company strategy at Morgan Stanley Healthcare Conference Sept 14

Quest Diagnostics CFO to discuss company strategy at Morgan Stanley Healthcare Conference Sept 14

Quest Diagnostics announced that Sam Samad, the company's Executive Vice President and CFO, will present on the company's strategy, performance, and market trends at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September...

Market News
Neutral
3 days ago
Quest Diagnostics expands Alzheimer's blood tests with FDA-cleared Elecsys pTau217 and new multi-biomarker panel.

Quest Diagnostics expands Alzheimer's blood tests with FDA-cleared Elecsys pTau217 and new multi-biomarker panel.

Quest Diagnostics announced two advancements in its Quest AD-Detect® blood tests for Alzheimer's disease. The company will add the FDA-cleared Elecsys® pTau217 test, the first single-assay blood test for amyloid pathology, to its portfolio by late 20...

Market News
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App